ArticleInfluenza and other respiratory viruses2026
Expanded Genomic Surveillance and Seasonal Comparisons of Human Respiratory Syncytial Virus Infections in Minnesota, USA, 2023-2025.
Article in Influenza and other respiratory viruses, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Genomic Surveillance Uncovers a Shift in Respiratory Syncytial Virus Subtype Dominance and the Local Expansion of Subclade B.D.E.1.7.Open forum infectious diseases · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
backgroundHuman respiratory syncytial virus (HRSV) imposes a substantial burden in the United States. The use of whole-genome sequencing (WGS) for public health surveillance of HRSV lags that for other viral pathogens. The objective of this study was to expand the scope and depth of WGS-based surveillance of HRSV in Minnesota, USA.
methodsHRSV-positive specimens collected from outpatients and inpatients from July 2023 to April 2025 were submitted to the Minnesota Public Health Laboratory for WGS. Genomes were sequenced using a tiled amplicon approach, characterized by lineage, phylogenetically compared to those from prior surveillance, and searched for mutations reported to affect monoclonal antibody susceptibility or fusion (F) protein function. Data from surveillance of HRSV-associated hospitalizations were incorporated for epidemiological analysis.
resultsContinuing WGS through 2025 generated 2975 HRSV genomes. Compared to those from 2023 to 2024, genomes from the 2024-2025 season were collected from greater proportions of patients with HRSV-associated hospitalizations, of older age, and from a broader geographical distribution. Subgroups A and B both exhibited significant differences in total genetic diversity by season (p < 0.001). Twenty subclades and lineage A.D.5.4 were not observed during the 2024-2025 season. F protein mutations were identified at 15 amino acid positions of epidemiological concern, of which 11 emerged homoplastically. Genomes from 39 hospitalized patients carried at least one of these mutations.
conclusionsContinuing WGS-based HRSV surveillance across multiple respiratory seasons yielded valuable insights into the emergence and evolution of viral lineages and the prevalence of mutations of concern among outpatient and inpatient infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.